Thomas Martin, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue, #522
San Francisco CA 94117
Phone415-353-2421
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPost-Doc Fellow/Scholar1996 Medicine
    University of California, San Francisco Clinical Fellowship
    University of California, San FranciscoResidency
    University of ConnecticutM.D.1989School of Medicine

    Collapse Overview 
    Collapse Overview
    A leading expert in hematology-oncology, Dr. Thomas Martin is associate director of UCSF's myeloma program and director of the unrelated donor transplantation programs for adults at UCSF Medical Center.

    Martin is clinical research director of hematologic malignancies (blood cancers) at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants, and he is involved in efforts to improve outcomes for patients who have transplants from unrelated donors.

    Martin earned an undergraduate degree at Cornell University and his medical degree at the University of Connecticut School of Medicine. After a medical residency at Harbor-UCLA Medical Center, he completed a fellowship in hematology-oncology at UCSF. In 1999, he joined MD Anderson Cancer Center as an assistant professor of medicine. In 2001, he returned to UCSF.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy. Blood Adv. 2024 Apr 04. Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek SS, Cheung A, Bylsma SA, Hansen E, Wolf JL, Wong SW, Shah N, Roybal KT, Martin TG, Ye CJ, Fong L. PMID: 38574299.
      View in: PubMed   Mentions:    Fields:    
    2. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv. 2024 01 09; 8(1):194-206. Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A, Banerjee A, Chastain K, Perales-Puchalt A, Stephenson T, Uhlar C, Kobos R, van der Holt B, Kruyswijk S, Kuipers MT, Groen K, Vishwamitra D, Skerget S, Cortes-Selva D, Doyle M, Zaaijer HL, Zweegman S, Verona RI, van de Donk NWCJ. PMID: 38052042; PMCID: PMC10787247.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. CD46-targeted theranostics for Positron Emission Tomography and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma. Clin Cancer Res. 2023 Dec 18. Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y, Liu B, Wiita AP, Flavell RR. PMID: 38109209.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    4. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study. Clin Lymphoma Myeloma Leuk. 2024 03; 24(3):194-202. Martin TG, Moreau P, Usmani SZ, Garfall A, Mateos MV, San-Miguel JF, Oriol A, Nooka AK, Rosinol L, Chari A, Karlin L, Krishnan A, Bahlis N, Popat R, Besemer B, Martínez-López J, Delforge M, Trancucci D, Pei L, Kobos R, Fastenau J, Gries KS, van de Donk NWCJ. PMID: 38052709.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024 03 15; 130(6):886-900. Nooka AK, Rodriguez C, Mateos MV, Manier S, Chastain K, Banerjee A, Kobos R, Qi K, Verona R, Doyle M, Martin TG, van de Donk NWCJ. PMID: 37960969.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 Sep 27; 13(1):152. Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špicka I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. PMID: 37752114; PMCID: PMC10522597.
      View in: PubMed   Mentions:    Fields:    
    7. Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. J Geriatr Oncol. 2023 Nov; 14(8):101623. Huang LW, Shi Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Boscardin WJ, Steinman MA, Olin RL. PMID: 37678052.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. Future Oncol. 2023 Nov; 19(34):2297-2311. Martin TG, Madduri D, Pacaud L, Usmani SZ. PMID: 37497629.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma. Oncol Ther. 2023 Sep; 11(3):313-326. Palmer S, Lin Y, Martin TG, Jagannath S, Jakubowiak A, Usmani SZ, Buyukkaramikli N, Phelps H, Slowik R, Pan F, Valluri S, Pacaud L, Jackson G. PMID: 37270762; PMCID: PMC10447673.
      View in: PubMed   Mentions:
    10. Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2023 08; 29(8):504.e1-504.e7. Zafar A, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Martin TG, Shah N, Banerjee R. PMID: 37244643.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 05 09; 13(1):72. Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špicka I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. PMID: 37156782; PMCID: PMC10166682.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    12. Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. J Comp Eff Res. 2023 06; 12(6):e220186. Krishnan A, Nooka AK, Chari A, Garfall AL, Martin TG, Nair S, Lin X, Qi K, Londhe A, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Usmani SZ. PMID: 37114426; PMCID: PMC10402759.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Cancer. 2023 07 01; 129(13):2035-2046. Martin TG, Mateos MV, Nooka A, Banerjee A, Kobos R, Pei L, Qi M, Verona R, Doyle M, Smit J, Sun W, Trancucci D, Uhlar C, van de Donk NWCJ, Rodriguez C. PMID: 36991547.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    14. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study. Br J Haematol. 2023 06; 201(5):935-939. Ge AY, Huang CY, Banerjee R, Knoche J, Chung A, Arora S, Martin TG, Wolf J, Wong SW, Wiita AP, Shah N. PMID: 36846905.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    15. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis. Curr Probl Cancer. 2023 06; 47(3):100953. Kennedy VE, Natsuhara K, Maringanti SA, Shah ND, Arora S, Wolf J, Martin TG, Aras MA, Chung A, Wong SW. PMID: 36807996.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. Transplant Cell Ther. 2023 02; 29(2):134.e1-134.e7. Martin TG, Capra M, Mohty M, Suzuki K, Quach H, Cavo M, Moreau P, Dimopoulos M, Yong K, Tekle C, Foster MC, Barnes Y, Risse ML, Mikhael J. PMID: 36372355.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    17. Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA. Haematologica. 2022 10 01; 107(10):2485-2491. Martin T, Richardson PG, Facon T, Moreau P, Perrot A, Spicka I, Bisht K, Inchauspé M, Casca F, Macé S, Van de Velde H, Suzuki K. PMID: 35734925; PMCID: PMC9521209.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    18. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):22-27. Martin T, Jackson CC, Pacaud L, Madduri D, Jagannath S. PMID: 36411210.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    19. Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia. 2022 12; 36(12):2917-2921. Slade M, Martin TG, Nathwani N, Fiala MA, Rettig MP, Gao F, Deol A, Buadi FK, Kaufman JL, Hofmeister CC, Gregory TK, Berdeja J, Chari A, Rosko A, Vij R. PMID: 36114265; PMCID: PMC10445424.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias. Br J Haematol. 2022 11; 199(4):520-528. Chung A, Banbury B, Vignali M, Huang CY, Asoori S, Johnson R, Kurtz T, Arora S, Wong SW, Shah N, Martin TG, Wolf JL. PMID: 36041779; PMCID: PMC9538250.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    21. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nat Biotechnol. 2023 04; 41(4):521-531. Shy BR, Vykunta VS, Ha A, Talbot A, Roth TL, Nguyen DN, Pfeifer WG, Chen YY, Blaeschke F, Shifrut E, Vedova S, Mamedov MR, Chung JJ, Li H, Yu R, Wu D, Wolf J, Martin TG, Castro CE, Ye L, Esensten JH, Eyquem J, Marson A. PMID: 36008610; PMCID: PMC10065198.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    22. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol. 2022 Nov; 109(5):504-512. Spicka I, Moreau P, Martin TG, Facon T, Martinez G, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yagci M, Cavo M, Risse ML, Asset G, Macé S, van de Velde H, Yong K. PMID: 35871357.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    23. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Adv. 2022 08 09; 6(15):4506-4515. Martin T, Mikhael J, Hajek R, Kim K, Suzuki K, Hulin C, Garg M, Quach H, Sia H, George A, Konstantinova T, Risse ML, Asset G, Macé S, van de Velde H, Moreau P. PMID: 35594559; PMCID: PMC9636327.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    24. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun. 2022 07 15; 13(1):4121. Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD, Mullins RD, Eyquem J, Wells JA, Wiita AP. PMID: 35840578; PMCID: PMC9287322.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    25. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022 Dec; 40(5):1020-1029. Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yagci M, Cavo M, Yong K, Risse ML, Asset G, Schwab S, Martinez G. PMID: 35653225; PMCID: PMC10084276.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    26. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2022 06; 28(6):309.e1-309.e9. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. PMID: 35247612; PMCID: PMC9198006.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021 12 14; 5(23):5344-5348. Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf J, Martin TG, Shah N, Wong SW. PMID: 34644387; PMCID: PMC9153014.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    28. Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series. Clin Transplant. 2022 03; 36(3):e14541. Dinh AR, Wong SW, Martin TG, Wolf JL, Webber AB. PMID: 34797567.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Evaluation of subcutaneous daratumumab injections in the ambulatory care setting. J Oncol Pharm Pract. 2022 Dec; 28(8):1819-1825. Tam AH, Jung Y, Young R, Huang CY, Wolf J, Shah N, Wong SW, Martin TG, Lo M. PMID: 34647506.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma. Future Oncol. 2021 Dec; 17(35):4849-4860. Banerjee R, Lo M, Martin TG. PMID: 34553603.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    31. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood Cancer Discov. 2021 09; 2(5):434-449. Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C. PMID: 34514432; PMCID: PMC8425277.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    32. Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma. J Immunother Cancer. 2021 07; 9(7). Sun H, Martin TG, Marra J, Kong D, Keats J, Macé S, Chiron M, Wolf JL, Venstrom JM, Rajalingam R. PMID: 34272304; PMCID: PMC8287616.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    33. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021 05 12; 11(5):89. Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. PMID: 33980831; PMCID: PMC8116334.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    34. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer. 2021 06 01; 127(11):1816-1826. Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A. PMID: 33735504; PMCID: PMC8252002.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    35. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2021 06; 27(6):477.e1-477.e7. Banerjee R, Marsal J, Huang CY, Lo M, Kambhampati S, Kennedy VE, Arora S, Wolf JL, Martin TG, Wong SW, Shah N. PMID: 33831353.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    36. Benzodiazepine and zolpidem prescriptions during autologous stem cell transplantation. EJHaem. 2021 May; 2(2):276-279. Banerjee R, Lazar AA, Dunn L, Knoche J, Lo M, Arora S, Wong SW, Wolf JL, Martin TG, Dhruva A, Shah N. PMID: 35845271; PMCID: PMC9175938.
      View in: PubMed   Mentions: 1  
    37. Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation. J Geriatr Oncol. 2021 05; 12(4):531-539. Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL. PMID: 33059999.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    38. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Clin Cancer Res. 2020 11 15; 26(22):6028-6038. Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. PMID: 32917735; PMCID: PMC7669584.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    39. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020 07 14; 4(13):2899-2911. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. PMID: 32589729; PMCID: PMC7362346.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    40. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nat Commun. 2020 04 22; 11(1):1931. Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. PMID: 32321912; PMCID: PMC7176739.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    41. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv. 2020 01 14; 4(1):181-190. Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W. PMID: 31935283; PMCID: PMC6960456.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    42. Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2020 05; 26(5):876-883. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG. PMID: 31785375.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    43. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells. 2019 11 26; 8(12). Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, Solanki M, Meng R, Lee H, Wiederschain D, Zhu C, Rak A, Anderson KC. PMID: 31779273; PMCID: PMC6953105.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    44. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2020 03; 34(3):938-941. Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, Shah N, Wiita AP. PMID: 31595037; PMCID: PMC7214267.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    45. Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2020 01; 26(1):189-196. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL. PMID: 31493541; PMCID: PMC6942208.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    46. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma. Mol Cancer Ther. 2019 11; 18(11):2008-2020. Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L, Kamperschroer C, Pascua E, Chen W, Delaria K, Farias S, Bateman M, Dushin RG, Chin SM, Van Blarcom TJ, Yeung YA, Lindquist KC, Chunyk AG, Kuang B, Han B, Mirsky M, Pardo I, Buetow B, Martin TG, Wolf JL, Shelton D, Rajpal A, Strop P, Chaparro-Riggers J, Sasu BJ. PMID: 31434693.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    47. Multiple Myeloma: Current Advances and Future Directions. Clin Lymphoma Myeloma Leuk. 2019 05; 19(5):255-263. Martin T, Huff CA. PMID: 31130488.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    48. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 06; 25(6):1218-1224. Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL. PMID: 30708189.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    49. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):9-22. Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. PMID: 30287200.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    50. Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma. J Oncol Pharm Pract. 2019 Jul; 25(5):1253-1257. Tan M, Kalin-Hajdu E, Narayan R, Wong SW, Martin TG. PMID: 30005587.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. Mol Cancer Ther. 2017 11; 16(11):2375-2386. Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M. PMID: 28878026.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    52. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leuk Lymphoma. 2017 08; 58(8):1872-1879. Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C. PMID: 28140719.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    53. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 12 01; 126(12):4640-4653. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. PMID: 27841764; PMCID: PMC5127683.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    54. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. PMID: 27587788; PMCID: PMC5524541.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    55. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 11; 22(11):1974-1982. Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. PMID: 27544285; PMCID: PMC5072749.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    56. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 05 26; 127(21):2561-8. Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. PMID: 26932802.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    57. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 06; 22(6):1030-1036. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. PMID: 26899561.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    58. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 07; 57(7):1560-6. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. PMID: 26490487.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    59. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. PMID: 25776193.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    60. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B. PMID: 25294123; PMCID: PMC4482758.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    61. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. PMID: 25243620.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    62. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. PMID: 24894413.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    63. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Oncology (Williston Park). 2013 Dec; 27 Suppl 3:4-10. Martin TG. PMID: 25184230.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    64. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. PMID: 23447001; PMCID: PMC4149337.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    65. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. PMID: 22571201; PMCID: PMC3744390.
      View in: PubMed   Mentions: 403     Fields:    Translation:HumansCTClinical Trials
    66. Autologous hematopoietic cell transplantation for high-risk ALL. Bone Marrow Transplant. 2011 Mar; 46(3):460-1. Linker C, Damon L, Martin T, Blume K, Forman S, Snyder D, Wolf J, Negrin R. PMID: 20531287.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    67. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008 Nov; 42(10):649-57. Damon L, Damon LE, Gaensler K, Kaplan L, Martin T, Rubenstein J, Linker C. PMID: 18679366; PMCID: PMC4372391.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    68. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. PMID: 17989720.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    69. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006 Sep; 38(6):421-6. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. PMID: 16892072; PMCID: PMC7091659.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    70. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant. 2006 Mar; 12(3):316-24. Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C. PMID: 16503501.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    71. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004 Aug 01; 104(3):649-54. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. PMID: 15069017.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    72. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Leukemia. 2003 Dec; 17(12):2538-40. Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M. PMID: 14523458.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    73. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2003 Oct; 9(10):643-8. Gunn N, Damon L, Varosy P, Navarro W, Martin T, Ries C, Linker C. PMID: 14569560.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    74. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003 Oct 15; 102(8):3052-9. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. PMID: 12842990.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    75. Adaptive decision making in a lymphocyte infusion trial. Biometrics. 2002 Sep; 58(3):560-8. Thall PF, Inoue LY, Martin TG. PMID: 12229990.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    76. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar; 13(3):450-9. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Körbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. PMID: 11996478.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    77. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001 Feb; 15(1):121-43. Martin TG, Linker CA. PMID: 11253604.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001 Feb; 15(1):97-120. Martin TG, Gajewski JL. PMID: 11253611.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    79. Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease. Bone Marrow Transplant. 2001 Feb; 27(4):355-64. Muench MO, Rae J, Bárcena A, Leemhuis T, Farrell J, Humeau L, Maxwell-Wiggins JR, Capper J, Mychaliska GB, Albanese CT, Martin T, Tsukamoto A, Curnutte JT, Harrison MR. PMID: 11313664.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    80. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2001; 7(10):568-75. Shimoni A, Gajewski JA, Donato M, Martin T, O'Brien S, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S. PMID: 11760089.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    81. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol. 2000 Jun; 109(4):770-2. Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin RE, Körbling M. PMID: 10929027.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    82. Interferon-induced thrombocytopenia: is it time for thrombopoietin. Hepatology. 1998 Nov; 28(5):1430-2. Martin TG, Shuman MA. PMID: 9794932.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    83. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med. 1997 Aug 15; 127(4):285-8. Martin TG, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, Shuman MA. PMID: 9265428.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    84. Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. Br J Haematol. 1996 Dec; 95(3):535-41. Meng YG, Martin TG, Peterson ML, Shuman MA, Cohen RL, Wong WL. PMID: 8943898.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    85. Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1991 Nov; 9(11):1939-44. Dimery IW, Brooks BJ, Winn R, Martin T, Shirinian M, Hong WK. PMID: 1941052.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Thomas's Networks
    Concepts (298)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (85)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.